Katirayi Leila, Namadingo Hazel, Phiri Mafayo, Bobrow Emily A, Ahimbisibwe Allan, Berhan Aida Yemane, Buono Nicole, Moland Karen Marie, Tylleskär Thorkild
Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA;
Elizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi.
J Int AIDS Soc. 2016 Jun 15;19(1):20919. doi: 10.7448/IAS.19.1.20919. eCollection 2016.
The implementation of lifelong antiretroviral treatment (ART) for all pregnant women (Option B+) in Malawi has resulted in a significant increase in the number of HIV-positive pregnant women initiating treatment. However, research has highlighted the challenge of retaining newly initiated women in care. This study explores barriers and facilitators that affect a woman's decision to initiate and to adhere to Option B+.
A total of 39 in-depth interviews and 16 focus group discussions were conducted. Eligible women were ≥18 years old, living with HIV and either pregnant and receiving antenatal care from a study site or had delivered a child within the last 18 months, breastfed their child and received services at one of the study sites. Eligible women were identified by healthcare workers (HCWs) in the antenatal clinic and ART unit. Focus groups were also conducted with HCWs employed in these departments. Qualitative data were analyzed using Maxqda version 10 (VERBI Software, Berlin, Germany).
The general perception towards the drug regimen used in Option B+ was positive; women reported fewer side effects and acknowledged the positive benefits of ART. Women felt hopeful about prolonging their life and having an HIV-uninfected baby, yet grappled with the fact that ART is a lifelong commitment. Women and HCWs discussed challenges with the counselling services for prevention of mother-to-child HIV transmission under the new Option B+ guidelines, and many women struggled with initiating ART on the same day as learning their HIV status. Women wanted to discuss their circumstances with their husbands first, receive a CD4 count and obtain an HIV test at another facility to confirm their HIV status. HCWs expressed concern that women might just agree to take the drugs to please them. HCWs also discussed concerns around loss to follow-up and drug resistance.
Although Option B+ has significantly increased the number of women initiating ART, there are still challenges that need to be addressed to strengthen initiation, adherence and retention in care. Strategies to strengthen the counselling services upon diagnosis need to be developed to improve same-day initiation of ART and long-term adherence.
在马拉维,为所有孕妇实施终身抗逆转录病毒治疗(方案B+)使得开始接受治疗的HIV阳性孕妇数量显著增加。然而,研究凸显了让新开始治疗的女性持续接受治疗的挑战。本研究探讨了影响女性决定开始并坚持方案B+治疗的障碍和促进因素。
共进行了39次深入访谈和16次焦点小组讨论。符合条件的女性年龄≥18岁,感染HIV,且要么怀孕并在研究地点接受产前护理,要么在过去18个月内分娩、母乳喂养孩子并在其中一个研究地点接受服务。符合条件的女性由产前诊所和抗逆转录病毒治疗科室的医护人员识别。还与这些科室的医护人员进行了焦点小组讨论。使用Maxqda 10版软件(VERBI Software,德国柏林)对定性数据进行分析。
对方案B+中使用的药物治疗方案总体看法积极;女性报告副作用较少,并认可抗逆转录病毒治疗的积极益处。女性对延长寿命和生育未感染HIV的婴儿感到充满希望,但也纠结于抗逆转录病毒治疗是一项终身承诺这一事实。女性和医护人员讨论了新的方案B+指南下预防母婴HIV传播咨询服务的挑战,许多女性在得知自己的HIV感染状况当天难以开始接受抗逆转录病毒治疗。女性希望先与丈夫讨论自己的情况,进行CD4细胞计数,并在另一家机构进行HIV检测以确认自己的HIV感染状况。医护人员担心女性可能只是为了取悦他们而同意服药。医护人员还讨论了失访和耐药性方面的问题。
尽管方案B+显著增加了开始接受抗逆转录病毒治疗的女性数量,但仍有一些挑战需要应对,以加强治疗的开始、坚持和持续接受治疗。需要制定策略来加强诊断时的咨询服务,以改善抗逆转录病毒治疗的当日开始和长期坚持治疗情况。